eli lilly tirzepatide Says Its Obesity Drug Zepbound Reduces Sleep Apnea FDA approves Eli Lilly's tirzepatide

0.6mg dose: 6.2% average weight loss 2.4mg dose: 12.5% average weight loss 3.6mg dose: 13.2% average weight loss 4.8mg dose: 14.9% average weight loss (planned treatment analysis) 4.8mg dose: 18.7% average weight loss (actual treatment received analysis) Placebo: 2.8% average weight loss The distinction between planned treatment and actual treatment received analyses matters

Another option is sharing an entre with a companion

However, the new cash-pay pricing may be preferable if youre near the income threshold and might not qualify, if you want to start treatment immediately (rather than waiting 4-6 weeks), if you find the application process burdensome, or if you prefer the simplicity of a fixed monthly price

The medication is fine